bluebird bio (NASDAQ:BLUE) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of bluebird bio (NASDAQ:BLUE - Free Report) in a research report sent to investors on Friday morning. The firm issued a sell rating on the biotechnology company's stock.

Several other equities analysts have also commented on the company. Royal Bank of Canada restated a "sector perform" rating and set a $4.00 price target on shares of bluebird bio in a research note on Thursday, August 15th. Wells Fargo & Company cut their price target on bluebird bio from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research note on Wednesday, September 25th. JPMorgan Chase & Co. downgraded bluebird bio from an "overweight" rating to a "neutral" rating in a research report on Thursday, August 15th. Bank of America dropped their price objective on bluebird bio from $4.00 to $3.00 and set a "buy" rating on the stock in a research report on Thursday, August 15th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating on shares of bluebird bio in a research report on Monday, September 16th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $4.63.

bluebird bio Trading Down 3.8 %

BLUE stock traded down $0.02 during midday trading on Friday, reaching $0.48. The company's stock had a trading volume of 3,785,210 shares, compared to its average volume of 7,536,947. The firm has a market capitalization of $52.50 million, a price-to-earnings ratio of -0.65 and a beta of 0.75. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.57 and a current ratio of 0.68. bluebird bio has a 1 year low of $0.45 and a 1 year high of $5.53. The stock has a fifty day simple moving average of $0.54 and a two-hundred day simple moving average of $0.85.

bluebird bio (NASDAQ:BLUE - Get Free Report) last announced its quarterly earnings results on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. The firm had revenue of $18.57 million for the quarter. bluebird bio had a negative net margin of 567.29% and a negative return on equity of 207.25%. On average, equities research analysts predict that bluebird bio will post -1.42 EPS for the current year.

Institutional Investors Weigh In On bluebird bio

Several institutional investors have recently added to or reduced their stakes in BLUE. Vanguard Group Inc. lifted its holdings in shares of bluebird bio by 19.6% during the first quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company's stock worth $13,438,000 after purchasing an additional 1,723,081 shares during the period. AQR Capital Management LLC lifted its holdings in shares of bluebird bio by 315.3% during the second quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company's stock worth $1,223,000 after purchasing an additional 1,013,144 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of bluebird bio by 19.4% during the second quarter. Bank of New York Mellon Corp now owns 685,757 shares of the biotechnology company's stock worth $675,000 after purchasing an additional 111,574 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of bluebird bio by 38.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company's stock worth $416,000 after purchasing an additional 90,139 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of bluebird bio by 25.4% during the second quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company's stock worth $288,000 after purchasing an additional 59,219 shares during the period. Institutional investors and hedge funds own 87.43% of the company's stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.